Price range: £60.00 through £475.00
Rated 5.0/5 from verified customers
| Pharmaceutical Manufacturer | Galenika |
| Brand | Ksalol |
| Medicinal ingredient | Alprazolam |
| Available Dose | 1mg |
| Pill Color | White |
| Manufacturing Origin | Europe |
Ksalol is a brand name for alprazolam, a benzodiazepine medicine used in certain countries for the short-term management of severe anxiety symptoms. Alprazolam is also used for panic disorder in some countries.
Alprazolam works by enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces excessive nerve activity in the central nervous system.
Ksalol 1mg contains one milligram of alprazolam per tablet. It is a relatively potent benzodiazepine strength, and its suitability depends on the patient's medical history, previous treatment and individual response.
Alprazolam may be prescribed in countries where it is authorised for:
Important UK information: Ksalol is not an established UK-licensed alprazolam brand. A product's availability in another country does not mean it is authorised for routine supply in the UK. Alprazolam also carries significant dependence and withdrawal risks.
Alprazolam belongs to the benzodiazepine class of medicines. It acts at GABA-A receptor complexes in the brain, increasing the inhibitory effects of GABA.
This reduces excessive activity in certain nerve pathways and produces calming, anxiolytic and sedative effects.
Immediate-release alprazolam generally begins producing noticeable effects within approximately 30 to 60 minutes, although the onset varies between individuals.
Alprazolam has an average elimination half-life of approximately 11 hours in healthy adults. Its clinical effects may last several hours, with longer persistence in some individuals.
Regular use can lead to tolerance and physical dependence. Stopping alprazolam suddenly after repeated use may cause significant withdrawal symptoms.
Usage guidance: Take alprazolam only as directed by a qualified prescriber. Do not increase the dose or frequency independently. If treatment needs to stop, a clinician may recommend a gradual, individually supervised dose reduction.
Alprazolam products are available in different strengths in countries where they are authorised. The appropriate dose depends on the patient's condition, age, medical history and response.
Ksalol 1mg is not a starting dose that should be assumed suitable for every patient. Even relatively small amounts of alprazolam can cause substantial sedation and impairment.
| Detail | Information |
|---|---|
| Product name | Ksalol |
| Generic name | Alprazolam |
| Active ingredient | Alprazolam |
| Strength | 1mg per tablet |
| Medicine class | Benzodiazepine |
| Uses in authorised markets | Short-term severe anxiety treatment and, in some countries, panic disorder |
| Typical onset | Approximately 30–60 minutes for immediate-release alprazolam |
| Average elimination half-life | Approximately 11 hours in healthy adults |
| UK controlled-drug status | Schedule 4 Part I controlled drug |
| UK product licensing | Ksalol is not an established UK-licensed brand |
Dosage warning: Alprazolam is a potent benzodiazepine. Taking more than prescribed can cause severe sedation, confusion, impaired coordination and dangerous breathing problems, particularly when combined with other depressants.
Alprazolam can cause side effects that affect alertness, memory, coordination and everyday functioning.
Commonly reported side effects include:
Some people may also experience confusion, changes in mood, irritability or unusual behavioural reactions.
Older adults and people taking other sedating medicines may be more susceptible to falls, excessive sedation and cognitive impairment.
Important safety information: Never combine alprazolam with alcohol. Alcohol can greatly increase sedation, impaired judgement and the risk of overdose.
Combining alprazolam with opioids, sleeping medicines or other central nervous system depressants can cause respiratory depression, coma or death.
Alprazolam may not be suitable for everyone. Discuss your medical history and other medicines with a qualified healthcare professional, particularly if you have:
Regular use of alprazolam can cause physical dependence. Abrupt withdrawal may lead to rebound anxiety, insomnia, agitation, tremors and, in severe cases, seizures.
A healthcare professional should supervise any reduction or discontinuation after regular use.
Alprazolam can impair memory, concentration, coordination and judgement, even when the person does not feel significantly drowsy.
Safety guidance: Avoid driving or operating machinery if your alertness or coordination is impaired. Do not combine alprazolam with alcohol or other sedatives without medical supervision. Store all benzodiazepines securely away from children.
Alprazolam is a controlled drug under UK law. Ksalol is a brand associated with markets outside the United Kingdom and should not be assumed to have a UK marketing authorisation.
Patients considering alprazolam treatment should obtain advice from an appropriately qualified UK clinician. Any supply must comply with applicable medicines, prescription and controlled-drug regulations.
Important checks include:
UK safety note: Websites advertising Ksalol without appropriate prescribing safeguards may expose patients to counterfeit products, incorrect strengths and serious health risks.
Ksalol is a brand name for alprazolam, a benzodiazepine medicine used for anxiety-related conditions in countries where it is authorised.
Ksalol and Xanax are brand names associated with the same active ingredient, alprazolam. Their manufacturers, packaging and regulatory authorisations may differ.
Immediate-release alprazolam may begin producing noticeable effects within approximately 30 to 60 minutes. Individual responses vary.
The noticeable effects generally last several hours. Alprazolam has an average elimination half-life of approximately 11 hours in healthy adults.
Alprazolam is a potent benzodiazepine, and 1mg can produce significant sedation and impairment. The appropriate strength must be determined by a prescriber.
Yes. Alprazolam can cause tolerance, physical dependence and withdrawal symptoms, including seizures following abrupt withdrawal in severe cases.
No. Alcohol increases the risk of severe sedation, impaired coordination and respiratory depression.
Ksalol is not an established UK-licensed alprazolam brand. Products marketed in other countries should not be assumed to have UK marketing authorisation.
Yes. Alprazolam is classified as a Schedule 4 Part I controlled drug under UK regulations.
Seek emergency medical assistance if someone taking alprazolam develops slow or difficult breathing, becomes unusually difficult to wake or loses consciousness.
Seek urgent medical attention if severe confusion, seizures or serious withdrawal symptoms occur.
Contact a healthcare professional if you experience persistent drowsiness, memory difficulties, changes in mood or signs of dependence.
Medical disclaimer: This article is for general educational purposes only and does not replace professional medical advice. Alprazolam is a controlled medicine and should only be used under appropriate medical supervision. Speak to a doctor or pharmacist if you are pregnant, breastfeeding or taking other medicines.
Reviews
There are no reviews yet.